ARTMS, Telix produce PSMA-11 in cyclotron

By staff writers

January 12, 2021 -- ARTMS and Telix Pharmaceuticals this week announced a milestone in their relationship to produce a prostate-specific membrane antigen (PSMA)-11-based radiopharmaceutical using cyclotrons.

The companies said that they successfully produced Telix's PSMA-11-based prostate cancer imaging product, TLX591-CDx, using multi-Curie quantities of gallium-68, produced using ARTMS' quantum irradiation system (QIS) technology. TLX591-CDx is being developed for detection of prostate cancer using PET.

The production run resulted in six-hour stability of TLX591-CDx, and testing exceeded all relevant quality control standards for both low- (50 mCi and 100 mCi) and midlevel output (over 2,500 mCi) production runs of gallium-68.

The companies first announced the gallium-68 agreement last year. ARTMS said it will continue to pursue cyclotron-produced gallium-68 and will focus on optimizing the technology's production potential while also meeting regulatory requirements for using the radiotracer in radiopharmaceutical kits like TLX591-CDx.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking